Trial · NCT01930890
Results by group44
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 44
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) | Placebo (211LE201) to BIIB023 3 mg/kg (211LE202) | Any event | 4 | participants | |
| Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) | BIIB023 3 mg/kg (211LE201) to BIIB023 3 mg/kg (211LE202) | Any event | 23 | participants | |
| Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) | Placebo (211LE201) to BIIB023 20 mg/kg (211LE202) | Any event | 7 | participants | |
| Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) | BIIB023 20 mg/kg (211LE201) to BIIB023 20 mg/kg (211LE202) | Any event | 19 | participants | |
| Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) | Placebo (211LE201) to BIIB023 3 mg/kg (211LE202) | Moderate or severe event | 2 | participants | |
| Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) | BIIB023 3 mg/kg (211LE201) to BIIB023 3 mg/kg (211LE202) | Moderate or severe event | 12 | participants | |
| Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) | Placebo (211LE201) to BIIB023 20 mg/kg (211LE202) | Moderate or severe event | 3 | participants | |
| Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) | BIIB023 20 mg/kg (211LE201) to BIIB023 20 mg/kg (211LE202) | Moderate or severe event | 6 | participants | |
| Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) | Placebo (211LE201) to BIIB023 3 mg/kg (211LE202) | Severe event | 0 | participants | |
| Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) | BIIB023 3 mg/kg (211LE201) to BIIB023 3 mg/kg (211LE202) | Severe event | 4 | participants | |
| Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) | Placebo (211LE201) to BIIB023 20 mg/kg (211LE202) | Severe event | 1 | participants | |
| Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) | BIIB023 20 mg/kg (211LE201) to BIIB023 20 mg/kg (211LE202) | Severe event | 3 | participants | |
| Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) | Placebo (211LE201) to BIIB023 3 mg/kg (211LE202) | Event related to dose-blinded treatment | 1 | participants | |
| Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) | BIIB023 3 mg/kg (211LE201) to BIIB023 3 mg/kg (211LE202) | Event related to dose-blinded treatment | 5 | participants | |
| Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) | Placebo (211LE201) to BIIB023 20 mg/kg (211LE202) | Event related to dose-blinded treatment | 1 | participants | |
| Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) | BIIB023 20 mg/kg (211LE201) to BIIB023 20 mg/kg (211LE202) | Event related to dose-blinded treatment | 4 | participants | |
| Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) | Placebo (211LE201) to BIIB023 3 mg/kg (211LE202) | Event related to MMF | 2 | participants | |
| Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) | BIIB023 3 mg/kg (211LE201) to BIIB023 3 mg/kg (211LE202) | Event related to MMF | 8 | participants | |
| Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) | Placebo (211LE201) to BIIB023 20 mg/kg (211LE202) | Event related to MMF | 2 | participants | |
| Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) | BIIB023 20 mg/kg (211LE201) to BIIB023 20 mg/kg (211LE202) | Event related to MMF | 9 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01930890/results